Paediatric and Congenital Cardiac Surgery and Cardiology, Azienda Ospedaliera Ospedali Riuniti, Ancona, Via Conca 71, 60128, Ancona, Italy.
Eur J Cardiovasc Nurs. 2012 Dec;11(4):419-22. doi: 10.1016/j.ejcnurse.2011.03.001. Epub 2012 Mar 6.
The modified Blalock-Taussig shunt is a surgical option in cyanotic patients. In our Institute heparin infusion therapy in the early postoperative period is used to reduce the risk of shunt thrombosis. This may produce haemorrhagic complications. Herein we describe the effect of a multidisciplinary audit to reduce the risk of haemorrhagic complications.
Between January 2005 and December 2009, 49 patients received a modified Blalock-Taussig shunt and anticoagulation therapy until the second administration of an antiplatelet drug. Four patients (8.1%) experienced a haemorrhagic event. A multidisciplinary audit was organized to analyze our anticoagulation protocol.
The cohort of patients was divided into group 1 and 2: patients without and with haemorrhagic events respectively. Group 2 was characterized by a low level of anticoagulation in the first postoperative day and received a dose of antithrombin III and an increase in heparin infusion. The result was excessive anticoagulation, evidenced by a significant increase in the aPTT from 44 to 138 sec (in Group 1: from 88 to 54 sec). Retrospectively the nursing staff found that these patients presented clinical signs heralding more significant bleeding.
The clinical audit depicted a difference between the two groups. Group 2 was initially characterized by heparin resistance and was consequently treated. The nursing staff found that retrospectively there were clinical signs heralding bleeding and created a risk score. Finally the analysis of this data produced a change in the institutional anticoagulation protocol and created a medical and nursing combined protocol for postoperative anticoagulation screening. Since then, the haemorrhagic complications have been reduced significantly.
改良的 Blalock-Taussig 分流术是发绀患者的一种手术选择。在我们的研究所,肝素输注疗法在术后早期用于降低分流术血栓形成的风险。这可能会产生出血性并发症。在此,我们描述了多学科审核以降低出血性并发症风险的效果。
2005 年 1 月至 2009 年 12 月,49 例患者接受改良 Blalock-Taussig 分流术和抗凝治疗,直至第二次给予抗血小板药物。4 例(8.1%)发生出血事件。组织了多学科审核,以分析我们的抗凝方案。
患者队列分为 1 组和 2 组:无出血事件的患者和有出血事件的患者。第 2 组在术后第 1 天抗凝水平低,并接受了抗凝血酶 III 剂量和肝素输注增加。结果是抗凝过度,表现在 aPTT 从 44 秒显著增加至 138 秒(第 1 组:从 88 秒增加至 54 秒)。回顾性地,护理人员发现这些患者出现了预示着更严重出血的临床迹象。
临床审核描绘了两组之间的差异。第 2 组最初表现为肝素抵抗,随后进行了治疗。护理人员发现,回顾性地,有预示出血的临床迹象,并创建了风险评分。最终,对这些数据的分析导致机构抗凝方案发生变化,并创建了术后抗凝筛查的医学和护理联合方案。自那时以来,出血性并发症显著减少。